论文部分内容阅读
目的:研究门冬氨酸鸟氨酸在乙型肝炎病毒(HBV)感染的胃肠道恶性肿瘤化疗中的保护作用观察。方法:将我院收治的92例胃肠道恶性肿瘤患者采取随机法分为实验组和对照组各46例。其中对照组采用FOLFOX化疗方案治疗,实验组从实行FOLFOX化疗方案的前三天便开始滴注门冬氨酸鸟氨酸;比较两组患者化疗后的体重变化、血液和肝脏的毒副反应,化疗前后的HBV DNA变化。结果:两组患者化疗后,实验组患者体重下降率低于对照组,其差异可进行统计(P<0.05);两组患者血液毒副反应发生率差异不大,不具统计性(P>0.05);实验组肝脏毒副反应发生率低于对照组,其差异可进行统计(P<0.05);两组患者化疗后,HBV DNA均有上升现象(P<0.05);而两组之间化疗前后的比较,差异不明显(P>0.05)。结论:将门冬氨酸鸟氨酸运用在HBV感染的胃肠道恶性肿瘤化疗中,可更好地保护患者肝脏功能,缓解患者临床症状,增强患者在化疗中的耐受性。
Objective: To study the protective effect of aspartate ornithine on the chemotherapy of gastrointestinal cancer infected by hepatitis B virus. Methods: A total of 92 patients with gastrointestinal cancer admitted to our hospital were randomly divided into experimental group and control group, with 46 cases in each group. The control group was treated with FOLFOX chemotherapy. The experimental group began to instil the aspartate ornithine from the first three days after the FOLFOX chemotherapy. The changes of body weight, blood and liver toxicity, Changes of HBV DNA before and after chemotherapy. Results: After chemotherapy, the weight loss rate of experimental group was lower than that of control group, and the difference was statistically significant (P <0.05). There was no significant difference between the two groups in the incidence of adverse reactions of blood (P> 0.05 ). The incidence of liver toxicity in the experimental group was lower than that in the control group (P <0.05). HBV DNA levels increased after chemotherapy in both groups (P <0.05) Before and after comparison, the difference was not significant (P> 0.05). Conclusion: The use of ornithine aspartate in HBV-infected gastrointestinal cancer chemotherapy can better protect the liver function of patients, relieve the clinical symptoms and enhance the patient’s tolerance in chemotherapy.